By Christian Ingram
Anti-osteoporotic therapy can reduce the risk of subsequent fragility-related osteoporosis fractures following an initial fracture by up to 40%, according to recently published data.
“Fragility fractures have a major impact on patients’ pain, function, and quality of life. They also account for a tremendous health care cost,” study author Harpreet S. Bawa, MD, stated in a press release.
“This study shows that initiation of anti-osteoporotic therapy following a fragility fracture can reduce subsequent fracture risk by 40% over 3 years and can prevent a subsequent fracture in one out of every 27 patients treated,” Bawa stated.
